Arkolith/Insider Trading/ENTA/Form 4

Kowalsky Matthew Paul

Chief Legal OfficerENANTA PHARMACEUTICALS INC (ENTA) · full profile →Form 4 · filed Feb 13, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 12, 2026Grant(A)4K—$05K
Feb 12, 2026Grant(A)1K—$01K
Feb 12, 2026Tax withholding(F)2K$14.25$27K4K

Transaction Codes

A
Grant / award
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002064832-26-000016) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for ENANTA PHARMACEUTICALS INC

Build

Ask your agent about ENTA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0002064832-26-000016"
Ask your agent
Use Arkolith to summarize insider buying and selling at ENANTA PHARMACEUTICALS INC
over the last 90 days and cite the filings.